Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Emily Bodnar has maintained a Buy rating on Agios Pharmaceuticals, setting a price target of $65.00. The positive outlook is driven by the early traction of Aqvesme (mitapivat) and strong commercial execution. Despite challenges from the REMS program, the initial prescription numbers indicate robust demand. Management's guidance on the thalassemia population and expectations for revenue growth support a significant sales ramp from 2Q–4Q 2026. Bodnar's analysis suggests a credible path for increasing mitapivat revenues, justifying the Buy recommendation on AGIO.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments